S&P 500   4,486.46
DOW   35,258.61
QQQ   372.65
S&P 500   4,486.46
DOW   35,258.61
QQQ   372.65
S&P 500   4,486.46
DOW   35,258.61
QQQ   372.65
S&P 500   4,486.46
DOW   35,258.61
QQQ   372.65
NASDAQ:AZN

AstraZeneca News Headlines

$59.29
-0.93 (-1.54 %)
(As of 10/18/2021 04:00 PM ET)
Add
Compare
Today's Range
$59.13
$59.87
50-Day Range
$55.56
$60.80
52-Week Range
$46.48
$61.34
Volume4.23 million shs
Average Volume9.52 million shs
Market Capitalization$183.69 billion
P/E Ratio41.17
Dividend Yield2.27%
Beta0.53

Media Mentions By Week

AstraZeneca Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

AZN
News Sentiment

0.19

0.36

Average
Medical
News Sentiment

Media Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

AZN Articles
This Week

29

48

AZN Articles
Average Week

Get AstraZeneca News Delivered to You Automatically

Sign up to receive the latest news and ratings for AZN and its competitors with MarketBeat's FREE daily newsletter.

AstraZeneca (NASDAQ AZN) News Headlines Today

SourceHeadline
marketwatch.com logoAstraZeneca Recommends Shareholders Reject TRC Capital Mini-Tender Bid - MarketWatch
marketwatch.com - October 18 at 8:38 AM
marketwatch.com logoPfizer and AstraZeneca vaccines were as effective as prior infection, U.K. study finds - MarketWatch
marketwatch.com - October 18 at 8:38 AM
marketwatch.com logoValneva shares spike after saying vaccine candidate outperformed AstraZeneca's - MarketWatch
marketwatch.com - October 18 at 8:38 AM
finance.yahoo.com logoValneva Soars as Covid Vaccine Candidate Shows Promise
finance.yahoo.com - October 18 at 8:38 AM
finance.yahoo.com logoValneva shares jump 30% after saying vaccine candidate outperformed AstraZeneca's
finance.yahoo.com - October 18 at 8:38 AM
finance.yahoo.com logoThailand to cease Sinovac vaccine use when stocks end this month
finance.yahoo.com - October 18 at 8:38 AM
finance.yahoo.com logoPfizer and AstraZeneca vaccines were as effective as prior infection, U.K. study finds
finance.yahoo.com - October 18 at 8:38 AM
ft.com logoValneva Covid jab produces stronger immune response than AstraZeneca vaccine - Financial Times
ft.com - October 18 at 3:37 AM
nasdaq.com logoAstraZeneca Recommends Shareholders Reject TRC Capital's Mini-Tender Offer - Quick Facts - Nasdaq
nasdaq.com - October 18 at 3:37 AM
markets.businessinsider.com logoAstraZeneca Recommends Shareholders Reject TRC Capital's Mini-Tender Offer - Quick Facts
markets.businessinsider.com - October 18 at 3:29 AM
finance.yahoo.com logoUPDATE 1-U.S. will accept mixed doses of vaccines from international travelers
finance.yahoo.com - October 15 at 7:54 PM
bloomberg.com logoAstraZeneca Wins Ruling Upholding Key Patent for Diabetes Drug - Bloomberg
bloomberg.com - October 15 at 6:41 PM
bloomberg.com logoAstraZeneca Reports Positive Results in Liver Cancer Drug Trial - Bloomberg
bloomberg.com - October 15 at 1:38 PM
finance.yahoo.com logoDon’t Count Out Covid-19 Monoclonal Antibody Treatments, Analyst Says. These Are the Stocks to Watch.
finance.yahoo.com - October 15 at 1:38 PM
markets.businessinsider.com logoAZN : Imfinzi Plus Tremelimumab Improves OS In Phase III Trial In Liver Cancer
markets.businessinsider.com - October 15 at 8:37 AM
marketwatch.com logoAstraZeneca Says Combination of Tremelimumab and Imfinzi Antibodies Boosted Liver Cancer Survival - MarketWatch
marketwatch.com - October 15 at 3:37 AM
finance.yahoo.com logoDoctor on Covid-19: ‘Let history guide our future actions’
finance.yahoo.com - October 14 at 2:47 PM
finance.yahoo.com logoHere's Why Astrazeneca (AZN) is a Strong Momentum Stock
finance.yahoo.com - October 14 at 12:35 PM
finance.yahoo.com logoAustralia's CSL reiterates manufacturing commitment with AstraZeneca COVID-19 vaccine - Yahoo Finance
finance.yahoo.com - October 14 at 7:35 AM
bloomberg.com logoAstraZeneca and Columbia University Irving Medical Center on Lessons Learned From the Pandemic - Bloomberg
bloomberg.com - October 13 at 3:54 PM
seekingalpha.com logoAstraZeneca COVID-19 jab will no longer be made in Australia - 9News - Seeking Alpha
seekingalpha.com - October 13 at 3:54 PM
finance.yahoo.com logoUPDATE 1-Russia says Sputnik Light is 70% effective against Delta variant
finance.yahoo.com - October 13 at 2:14 PM
fortune.com logoRussia furiously denies stealing AstraZeneca ‘blueprint’ to make Sputnik V COVID-19 vaccine - Fortune
fortune.com - October 12 at 4:13 AM
reuters.com logoS.Korea to donate 1.1 mln doses of AstraZeneca COVID-19 vaccine to Vietnam, 470000 doses to Thailand - Reuters
reuters.com - October 12 at 4:13 AM
nasdaq.com logo4 Biotech Stocks To Watch As AstraZeneca Posts COVID Antibody Cocktail Breakthrough - Nasdaq
nasdaq.com - October 12 at 1:14 AM
MarketBeat logoAstraZeneca's (AZN) Buy Rating Reaffirmed at Deutsche Bank Aktiengesellschaft
americanbankingnews.com - October 11 at 4:16 PM
finance.yahoo.com logoMerck Stock Slips Slightly As It Asks FDA To Authorize Covid Pill
finance.yahoo.com - October 11 at 3:14 PM
finance.yahoo.com logoMerck seeks authorization for what would be first pill to treat COVID-19, and AstraZeneca reports positive results for antibody treatment
finance.yahoo.com - October 11 at 12:39 PM
businessinsider.com logoAstraZeneca antibody drug cuts severe COVID-19 by 50%: study - Business Insider
businessinsider.com - October 11 at 10:14 AM
finance.yahoo.com logoAstraZeneca Says Drug Reduces Risk of Developing Severe Covid by 50%
finance.yahoo.com - October 11 at 10:14 AM
reuters.com logoAstraZeneca antibody cocktail succeeds in late-stage study to treat COVID-19 - Reuters
reuters.com - October 11 at 7:39 AM
finance.yahoo.com logoAstraZeneca Says Drug Cocktail Effective in Reducing Risk of Developing Severe Covid-19
finance.yahoo.com - October 11 at 7:39 AM
marketwatch.com logoAstraZeneca's AZD7442 Trial Showed Reduced Risk of Developing Severe Covid-19 - MarketWatch
marketwatch.com - October 11 at 2:38 AM
finance.yahoo.com logoCosta Rica government unveils migrant COVID-19 vaccination campaign
finance.yahoo.com - October 8 at 11:28 PM
finance.yahoo.com logo10 Stocks to Buy in 2021 According to Carl Tiedemann’s TIG Advisors
finance.yahoo.com - October 8 at 8:42 AM
marketwatch.com logoAstraZeneca: Tezepelumab Gets FDA Orphan Designation for Eosinophilic Esophagitis - MarketWatch
marketwatch.com - October 8 at 8:23 AM
finance.yahoo.com logoTezepelumab granted Orphan Drug Designation in the US for eosinophilic esophagitis
finance.yahoo.com - October 8 at 8:23 AM
finance.yahoo.com logoAstraZeneca's experimental asthma gets an orphan drug designation for another disease
finance.yahoo.com - October 8 at 8:23 AM
nasdaq.com logoNovember 26th Options Now Available For AstraZeneca (AZN) - Nasdaq
nasdaq.com - October 7 at 7:48 PM
finance.yahoo.com logoBooster discussion 'a bit convoluted': Doctor
finance.yahoo.com - October 7 at 7:30 PM
finance.yahoo.com logoMixing & matching covid boosters ‘might be a great opportunity’: Doctor
finance.yahoo.com - October 6 at 4:42 PM
finance.yahoo.com logoFortress Biotech Announces Closing of Acquisition of Caelum Biosciences by AstraZeneca - Yahoo Finance
finance.yahoo.com - October 6 at 11:09 AM
marketwatch.com logoAstraZeneca Requests US FDA Emergency Use Authorization for Covid-19 Prophylaxis - MarketWatch
marketwatch.com - October 6 at 4:58 AM
finance.yahoo.com logoAstraZeneca (AZN) Seeks Emergency Nod for COVID Prevention Drug
finance.yahoo.com - October 6 at 4:58 AM
finance.yahoo.com logo'If you’re not vaccinated, get vaccinated': Doctor
finance.yahoo.com - October 6 at 4:58 AM
bloomberg.com logoAstraZeneca Seeks U.S. Emergency Approval for Covid Antibody - Bloomberg
bloomberg.com - October 5 at 4:18 AM
reuters.com logoFinancial, travel stocks weigh on FTSE 100; Morrisons drops - Reuters
reuters.com - October 4 at 12:42 PM
nasdaq.com logoAstraZeneca's Enhertu Receives Fourth U.S. Breakthrough Therapy Designation - Nasdaq
nasdaq.com - October 4 at 8:15 AM
finance.yahoo.com logoCompugen Announces Milestone Payment from AstraZeneca Triggered by First Patient Dosed with TIGIT Bispecific Derived from COM902 - Yahoo Finance
finance.yahoo.com - October 4 at 7:42 AM
reuters.com logoOil stocks, AstraZeneca support FTSE 100; Morrisons drops - Reuters
reuters.com - October 4 at 7:42 AM
Get AstraZeneca News Delivered to You Automatically

Sign up to receive the latest news and ratings for AZN and its competitors with MarketBeat's FREE daily newsletter.

This page was last updated on 10/19/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.